CTOs on the Move

deCODE genetics

www.decode.com

 
deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.decode.com
  • 1000 Winter St Ste 3100
    Waltham, MA USA '02451
  • Phone: 354.570.1900

Executives

Name Title Contact Details

Similar Companies

Intact Vascular

Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular Systemâ„¢ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.

Onconano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.

Verseau Therapeutics

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.

Mind Medicine

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.